P-BCMA-101 Shows Early Effectiveness in First Multiple Myeloma Patients Treated in Phase 1 Trial
P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and effective in relapsed or refractory multiple myeloma patients, results from the first three patients enrolled…